Meeting
2011 ASCO Annual Meeting
Analysis of outcomes in patients (pts) with relapsed/refractory acute promyelocytic leukemia (APL) treated with and without high-dose chemotherapy and hematopoietic stem cell transplantation (HCT).
Authors
N. Pemmaraju
University of Texas M. D. Anderson Cancer Center, Houston, TX
N. Pemmaraju , F. Ravandi , G. Rondon , S. Giralt , J. Chen , S. Pierce , R. E. Champlin , M. De Lima , M. Qazilbash
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Allogeneic Bone Marrow
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6608)
Abstract #
6608
Poster Bd #
39E
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Allogeneic stem cell transplantation for patients over age 65 with acute myelogenous leukemia and myelodysplastic syndrome.
First Author: Henry Jacob Conter
Poster
2020 ASCO Virtual Scientific Program
Role of high-dose chemotherapy with autologous stem cell transplantation for primary central nervous system lymphoma: A systematic review.
First Author: Shaha Nabeel
Poster
2022 ASCO Annual Meeting
Non-myeloablative allogeneic blood or marrow transplantation (AlloBMT) with post-transplant cyclophosphamide (PTCy) for peripheral T-cell lymphoma (PTCL): Improved outcomes with peripheral blood (PB) allografts and increased total body irradiation (TBI) to 400 cGV.
First Author: Cole Harris Sterling
Poster
2018 ASCO Annual Meeting
ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).
First Author: Olalekan O. Oluwole